Exness, a well-known forex and contracts for differences brokerage brand, reported the monthly trading volume for March to be $3.86 trillion, recovering from the previous month’s $3.53 trillion. It was a monthly increase of 9.3 percent.

Strong Demand for a Broker

Despite the recovery last month, the volumes remained marginally lower from $3.87 trillion the broker reported in January. Year-over-year, too, the monthly volumes remained almost flat as the figure was at $3.88 trillion in March 2023.

Exness operates globally and has been aggressively expanding services in emerging markets like Asia, Africa, and Latin America. The Cyprus-headquartered brokerage obtained licenses in South Africa and Kenya while establishing its first Latin American presence with an office in Uruguay.

Trading demand on the platform peaked last October at $4.8 trillion. The broker, however, could not maintain the astronomical demand, as it corrected in the next consecutive months to $3.94 trillion and $3.61 trillion, respectively.

Trading volume growth on Exness has been exponential over the years. Demand plummeted after the brokers followed the market to witness a sudden spike in March 2020 due to the pandemic's impacts. But then, gradually, it started to pick up, crossing the $1 trillion milestone in October 2021, $2 trillion in March 2022, $3 trillion in February 2023, and then $4 trillion in August 2023.

A Record in Active Traders

Although the latest monthly volume remained lower than the peak, the number of active clients at 836,873 on the platform hit a record. The figure jumped about 9.2 percent month-over-month. Interestingly, despite the ebb and flow of trading volume, the number of active clients on the platform maintained an almost consistent uptrend.

Meanwhile, two top executives of Exness left the company in the past couple of months. Damian Bunce, who was the broker’s Chief Customer Officer, resigned in February and recently joined GTN as the CEO for Middle Eastern operations. Elena Krutova, the former Chief Administrative Officer at Exness, also moved recently to a pharmaceutical company.